Considering the emerging efficacy of X‐containing regimens in relapsed/refractory MM, including heavily pretreated anti‐BCMA subset, X‐containing combinations with novel IMiDs, PIs, or mAbs warrant investigation in earlier lines of therapy, including first relapse [11, 12, 14]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.